Latest Breaking News On - Corina dutcus - Page 1 : comparemela.com

Pembrolizumab Plus Lenvatinib Misses Both Survival End Points in Advanced, Recurrent Endometrial Cancer

The combination of pembrolizumab and lenvatinib failed to produce a statistically significant improvement in progression-free survival and overall survival vs platinum-based chemotherapy with carboplatin and paclitaxel as frontline therapy in patients with advanced or recurrent endometrial cancer whose disease in mismatch repair proficient/not microsatellite instability–high or mismatch repair deficient.

Gregory lubinieckiCorina dutcusMerck research laboratoriesGlobal clinical developmentOncology global clinical development leadEisai incGynecologic oncologyThe phase 3 leap 001 trial

acnnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from acnnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesDamini chokshiPeter dannenbaumJohn infantiGregory lubinieckiJulie cunninghamCorina dutcusGlobal clinical developmentMerck co incUnited states research laboratoriesEisai co ltdUnited states provide updateFirst line treatmentRecurrent endometrialVice presidentUnited states research

Eisai and Merck & Co , Inc , Rahway, NJ, USA Provide Update on Phase 3 LEAP-001 Trial Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma

Eisai and Merck & Co , Inc , Rahway, NJ, USA Provide Update on Phase 3 LEAP-001 Trial Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma
jcnnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jcnnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesDamini chokshiJulie cunninghamPeter dannenbaumCorina dutcusJohn infantiGregory lubinieckiMerck co incGlobal clinical developmentUnited states research laboratoriesEisai co ltdVice presidentUnited states researchSenior vice presidentOncology global clinical development lead

Eisai And Merck & Co , Inc , Rahway, NJ, USA Provide Update On Phase 3 LEAP-001 Trial Evaluating LENVIMA (Lenvatinib) Plus KEYTRUDA (Pembrolizumab) As

Eisai And Merck & Co , Inc , Rahway, NJ, USA Provide Update On Phase 3 LEAP-001 Trial Evaluating LENVIMA (Lenvatinib) Plus KEYTRUDA (Pembrolizumab) As
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

United statesJulie cunninghamPeter dannenbaumCorina dutcusGregory lubinieckiDamini chokshiJohn infantiUnited states research laboratories weGlobal clinical developmentEisai co ltdMerck co incUnited states provide updateFirst line treatmentRecurrent endometrial carcinomaVice presidentUnited states research laboratories

Merck and Eisai s Keytruda-Lenvima combo comes up short yet again, this time in endometrial cancer

Merck and Eisai s Keytruda-Lenvima combo comes up short yet again, this time in endometrial cancer
fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.

Gregory lubinieckiCorina dutcusMerck research laboratories